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Colorectal cancer (CRC) is the third most common cancer worldwide, ranking as 
high as the second leading cause of cancer-related deaths in industrialized countries. 
Consistent with immunosurveillance theory, the immune system is crucial to protect the 
host from developing tumors, and the major players in tumoral immunity are effector 
T cells. Anyway, cancer cells develop strategies of immunoevasion influencing the can-
cer-specific lymphocyte priming, activation, and effector function. Therefore, the T cell 
subsets that mature during the stages of tumor growth, differently contribute to disease 
progression and/or regression. In our study, we analyzed the intra-tumoral and periph-
eral T cell subsets’ distribution in 30 patients with CRC, in order to clarify their functional 
role toward cancer. We found that percentage of infiltrating effector T cells decreased in 
cancer tissue than in healthy mucosa and that the tumor microenvironment negatively 
influences the cytolytic activity of T lymphocytes reactive to cancer cells. Moreover, we 
found that the tumor tissue was infiltrated by a large amount of “not effector” T (neT) 
cells with a regulatory or an anergic profile, which are unable to kill cancer cells, may 
be contributing to the CRC promotion. The presence of neT cells was investigated also 
in the peripheral blood of CRC patients, demonstrating that the peripheral T regulatory 
cells can inhibit the proliferation of effector T cells, confirming their immunosuppressive 
properties. Finally, monitoring the changes in circulating neT cells’ frequencies after the 
tumor removal, we confirmed the role of cancer in the modulation of immune system, in 
particular, in supporting a Tregs-mediated immunosuppression.
Keywords: colorectal cancer, tumor-infiltrating lymphocytes, regulatory T  cells, not effector T  cells, T helper, 
tumor microenvironment, antitumor immune responses
inTrODUcTiOn
Colorectal cancer (CRC) is the third most common cancer worldwide, ranking as high as the second 
leading cause of cancer-related deaths in industrialized countries (1). Colorectal carcinogenesis 
represents a heterogeneous process with a differing set of somatic molecular alterations, influenced 
by diet, environmental/microbial exposures, and host immunity. CRC usually begins as benign 
Abbreviations: CRC, colorectal cancer; TILs, tumor-infiltrating lymphocytes; Tcc, T cell clones; Tregs, T regulatory cells; neT 
Tcc, non-effectors T cell clones; Teff, T effectors cells.
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polyps, sometimes referred as pre-cancerous, i.e., adenomatous 
polyps and evolves through the stepwise accumulation of genetic/
epigenetic alterations; so, the genotypic variations have a high 
impact, but in addition to some host factors, such as the cells of 
the immune response.
Consistent with immunosurveillance theory, the immune 
system is important to protect the host from developing tumors 
(2), but that the cancer cells can develop immunoevasion strate-
gies (3) and also, the immune cells can act, supporting the tumor 
progression (4). The major players of adaptive immunity are 
effector T  cells, but the tumoral immunoevasion mechanisms 
appear to influence diverse steps in cancer-specific lymphocyte 
priming, activation, and effector function (5). Therefore, the 
T cell subsets that develop during the stages of cancer growth, 
differently contribute to disease progression and/or regression. 
In particular, CD45RO+ memory T lymphocytes, cytotoxic CD8+ 
T cells (CTLs) and interferon (IFN)-γ-producing T helper1 cells 
(Th1) have been found to be associated with prolonged survival in 
CRC, irrespective of tumor stage (6–8), while the role of Th2 cells 
in colon cancer is mainly harmful as IL-4 directly and indirectly 
favors tumor growth (9–11). CD4+ T cells are now known to dif-
ferentiate into additional effector T-cell subsets (i.e., Th17, Th9, 
follicular helper T, Th22) with contrasting and unclear roles in 
the development of CRC (12–14) as well as immunosuppressive 
cells, like exhausted, anergic/tolerant, and subsets of regulatory 
T cells (Tregs) that can favor cancer progression (15–18). In fact, 
the CD4+ CD25+ Foxp3+ Tregs subpopulation may exert a critical 
role in cancer promotion (19, 20).
Regulatory T  cells are essential in the maintenance of 
immune homeostasis as illustrated by spontaneous autoimmune 
disease development when Tregs are rendered deficient (21, 22). 
Conversely, it is now well verified that a large number of Tregs 
infiltrate the tumor tissues of different cancers (breast, lung, 
pancreas, and ovary) (23–26) and their abundant presence is 
often associated with poor clinical prognosis and negatively cor-
related with patients’ survival (27). Notably, decreased ratios of 
tumor-infiltrating CD8+ T cells to FOXP3+ Tregs were shown to 
correlate with poor prognosis, especially in patients with breast 
(28), gastric (18), and ovarian cancer (29). By contrast, reports 
show that a high intra-tumoral frequency of Tregs is correlated 
with a good prognosis, in patients with Hodgkin lymphoma or 
CRC (10, 19, 30–32). These conflicting results may arise from 
an improper interpretation of the heterogeneous FOXP3+ cells 
(i.e., “effector” Tregs and non-Tregs) (33) as a single population 
of Tregs.
Thus, it is critically important to assess the functional prop-
erties of Tregs in the tumor tissues in order to evaluate their 
contribution to anticancer immune response.
In this study, we have characterized the tumor-infiltrating 
lymphocytes’ subsets in CRC patients to clarify their protective or 
favoring role toward cancer. The presence of anti-tumoral T cells 
or not effector T (neT) cells was investigated also in the periph-
eral blood of the same CRC patients, in order to evaluate if the 
peripheral T cell distribution mirror the intra-tumoral immune 
response. Finally, we dynamically investigated the changes in 
circulating Tregs’ frequencies after the tumor removal to assess 
the impact of cancer cells in the induction of Tregs.
MaTerials anD MeThODs
Patients
Thirty patients with CRC (18 males and 12 females, mean age 
67.3 years) and 30 healthy controls were enrolled after obtaining 
informed consent and approval of the local ethical committee 
(Comitato Etico Area Vasta Centro). Specifically, CRC patients’ 
characteristics are summarized in Table 1. Cancer samples were 
classified as colorectal adenocarcinoma according to the TNM 
classification of colorectal tumors. All patients underwent surgi-
cal resection of the primary lesion but did not receive chemo-
therapy; patients with evidence of serious illness, immunodeficit, 
or autoimmune or infectious diseases were excluded. As healthy 
controls, we enrolled asymptomatic patients, matched with 
respect to age and sex.
generation of T cell clones (Tcc) from 
Tils of the neoplastic colonic Tissue
Surgical specimens of CRC tissue were dissociated in order to 
isolate tumor-infiltrating lymphocytes (TILs). In particular, tis-
sue pieces from each patient were obtained from three different 
sites, namely: central tumor (CT), marginal tumor (MT), and 
surrounding healthy mucosa (HM). First, tissue pieces were 
dissociated with the Tumor Dissociation Kit, human (Miltenyi 
Biotech, UK) in combination with the gentleMACS™ Octo 
Dissociator (Miltenyi Biotech, Germany), to obtain a gentle 
and rapid generation of single-cell suspensions. Then, TILs 
were magnetically isolated with anti-human CD3 microbeads 
(Miltenyi Biotech, UK) and cloned under limiting dilution, 
as described previously (34). Briefly, ingle T-cell blasts were 
seeded in microwells (0.3  cells/well) in RPMI 1640 culture 
medium (SERO-Med GmbH, Wien) supplemented with 10% 
FCS HyClone (Gibco Laboratories, Grand Island, NY), in the 
presence of 2  ×  105 irradiated (9,000  rad) peripheral blood 
mononuclear cells (PBMC), phytohemagglutinin (0.5% vol/
vol), and recombinant human interleukin-2 (IL-2) (50  U/ml) 
(PeproTech, USA). At weekly intervals, 2 × 105 irradiated PBMC 
and IL-2 were added to each micro-culture to maintain the 
expansion of growing clones. The Tcc were evaluated for their 
surface markers and functional properties: in detail cytokine 
profile and cell cytotoxicity.
Phenotypic and Functional 
characterization of isolated Tcc
We analyzed the Tcc’ surface markers (CD3, CD4, CD8, 
CD25, CCR7, CD45RA, CD45 RO, and CD28) expression by 
flow cytometry using a BD FACScan cytofluorimeter as pre-
viously described (34). A total of 104 events for each sample 
was acquired. To assess the cytokines’ production Tcc were 
resuspended at a concentration of 106 cells/ml medium and 
cultured for 36  h in the presence of PMA (10  ng/ml) plus 
ionomycin (200 ng/ml). Cell-free supernatants were collected 
and assayed in duplicate for IFN-γ, IL-4, and IL-17, content by 
commercial ELISA kits (Bio-Source International, Camarillo). 
The supernatants presenting cytokine levels that were 5 SD 
above the mean levels in control supernatants derived from 
Table 1 | Clinical characteristics of colorectal cancer (CRC) patients: T cell clones (Tcc) generated and pre/postoperative values of circulating CD4+ regulatory T cells 
(Tregs).
code cea (mean ± sD) TnM Tcc obtained number of intra-tumoral 
Tregs
Preoperative values 
of Tregs
Postoperative values 
of Tregs
Crc 01 4.98 ± 1.48 pT3 NO Mx 21 1 2.4 1.9
Crc 02 3.69 ± 1.82 pT3 NO Mx 11 6 6.3 4.6
Crc 03 3.65 ± 2.12 pT3 N2a Mx 17 4 4.2 3.4
Crc 04 3.50 ± 1.65 pT3 NO Mx 15 6 5.4 4.2
Crc 05 4.28 ± 1.89 pT3 N1B Mx 20 4 4.5 3.6
Crc 06 4.30 ± 2.74 pT2 NO Mx 10 1 2.6 2.1
Crc 07 3.90 ± 1.65 pT3 N2a Mx 21 2 3.4 2.9
Crc 08 2.50 ± 1.43 pT2 NO Mx 17 3 3.5 1.9
Crc 09 4.37 ± 2.35 pT3 N2a Mx 15 2 2.9 2.2
Crc 10 4.25 ± 1.89 pT2 NO Mx 12 3 3.9 3.2
Crc 11 4.50 ± 2.38 pT3 N2a Mx 32 3 3.7 3.1
Crc 12 3.50 ± 2.62 pT2 NO Mx 24 2 3.8 2.8
Crc 13 4.36 ± 1.72 pT3 N2a Mx 27 6 4.5 3.5
Crc 14 4.20 ± 1.69 pT2 NO Mx 35 0 2.3 1.9
Crc 15 3.90 ± 2.15 pT3 NO Mx 30 1 3.4 2.5
Crc16 2.50 ± 1.62 pT3 NO Mx 38 1 3.6 2.8
Crc 17 5.09 ± 2.33 pT2 NO Mx 41 1 2.7 1.5
Crc 18 4.90 ± 2.63 pT2 NO Mx 27 1 3.4 1.9
Crc 19 4.90 ± 1.56 pT3 N2a Mx 25 2 3.5 2.8
Crc 20 3.50 ± 1.68 pT3 N2a Mx 36 1 2.8 2.1
Crc 21 4.95 ± 2.12 pT3 NO Mx 31 4 4.3 3.5
Crc 22 3.93 ± 2.63 pT3 NO Mx 26 1 2.9 2.2
Crc 23 4.20 ± 1.84 pT3 N2a Mx 28 2 3.7 2.9
Crc 24 3.80 ± 2.32 pT3 N2a Mx 32 1 2.4 1.5
Crc 25 2.66 ± 2.72 pT2 NO Mx 30 5 4.1 3.6
Crc 26 4.58 ± 1.98 pT2 NO Mx 30 3 3.8 3.1
Crc 27 4.90 ± 1.85 pT3 N2a Mx 26 1 3.2 2.1
Crc 28 4.62 ± 1.98 pT3 N2a Mx 37 0 2.8 1.8
Crc 29 4.36 ± 2.62 pT3 N2a Mx 25 2 3.6 3.1
Crc 30 2.50 ± 1.62 pT3 NO Mx 42 1 3.7 2.9
All CRC patients 4.04 ± 2.36 Colorectal adenocarcinoma 781 70 3.58 ± 0.88 2.72 ± 0,79
CEA, antigencarcinoembrionic.
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irradiated antigen-presenting cells alone were regarded as 
positive. Based on the cytokine profile and the CD4/CD8 
expression, we divided the Tcc into the following groups: Th1/
Tc1 (only IFN-γ), Th2/Tc2 (only IL-4), Th0/Tc0 (IL-4 + IFN-γ), 
and Th17/Tc17 (IL-17). Tcc unable to produce IFN-γ, IL-4, and 
IL-17 were analyzed by flow cytometry for FoxP3, TGF-beta, 
and IL-10 markers’ expression. Fluorochrome-conjugated anti-
human (IL-10, TGF-β, and FoxP3) mAbs were purchased from 
eBioscience (San Diego, CA, USA). For intracellular analysis, 
the blasts were stimulated using the Leukocyte Activation 
Cocktail, with BD GolgiPlug™ (BD Pharmingen), and stained 
with anti-IL-10, anti-TGF-β, and anti-FoxP3 mAbs. For the 
FoxP3 detection, Tcc were fixed and permeabilized using the 
BD Pharmingen Human FoxP3 Buffer Set (BD Biosciences). Tcc 
that were negative for FoxP3, IL-10, and TGF-β were defined as 
Tnull, and Tcc that were positive for FoxP3, IL-10, and TGF-β 
were defined as Tregs.
Flow cytometric Detection of granzyme a
Granzyme A expression by Tcc was assessed according to the 
manufacturer’s instructions (BD Biosciences, NJ, USA). The 
different subpopulations of Tcc were tested for their ability to 
kill P815 target cells upon anti-CD3 mAb activation (5 µg/ml) 
by evaluating the percentage of AnnexinV-binding cells by flow 
cytometry and using the FACSDiva software.
analysis of Peripheral and intra-Tumoral  
T cell subsets in crc Patients
For CRC patients, heparinized venous blood samples were 
collected on the day of the surgery (T =  0) and 2  weeks after 
(T = 14) the removal and PBMCs were isolated by density gradi-
ent centrifugation. By flow cytometry, TILs isolated from dissoci-
ated tumor tissue and PBMC samples were characterized for the 
expression of CD4, CD8, CD25, CD127, IFN-γ, IL-4, IL-17, and 
FoxP3 using intracellular cytokine staining. Briefly, fresh PBMCs 
were cultured in RPMI 1640 culture medium (SERO-Med 
GmbH, Wien) supplemented with 10% FCS HyClone (Gibco 
Laboratories, Grand Island, NY, USA) and stimulated for 5  h 
using the Leukocyte Activation Cocktail, with BD GolgiPlug™ 
(BD Pharmingen). Cells were first stained for the surface anti-
gens, then fixed with 4% (w/v) paraformaldehyde and permeabi-
lized with 0.5% saponin, followed by intracellular staining with 
anti-IL-4, anti-IL-17, and anti-IFN-γ mAbs (BD Biosciences). 
For the detection of peripheral Tregs, PBMC were fixed and 
permeabilized using the BD Pharmingen Human FoxP3 Buffer 
Set (BD Biosciences). A minimum of 10,000 events was acquired 
FigUre 1 | T cell clones (Tcc) obtained from colorectal cancer (CRC) patients. (a) The histogram represents the number of CD4+ and CD8+ Tcc isolated from the 
three different sites, namely central tumor, marginal tumor, and surrounding healthy mucosa. (b) A representative flow cytometry analysis of a CD4+ Tcc: anti-CD3, 
anti-CD4, anti-CD8 mAb (filled curve), or isotype control (empty curve).
4
Niccolai et al. T Subsets in CRC
Frontiers in Immunology | www.frontiersin.org December 2017 | Volume 8 | Article 1900
for each test and data were analyzed using DIVA software. Based 
on the cytokine profile and the extracellular markers expression, 
we identified the following T cell subsets: Th1/Tc1 (only IFN-γ), 
Th2/Tc2 (only IL-4), Th0/Tc0 (IL-4 + IFN-γ), Th17/Tc17 (IL-17), 
and Treg/Tcreg (CD25+, CD127−, FoxP3+) (35). We defined as 
Tnull/Tcnull the percentage of CD4+/CD8+ T  cell that did not 
produce any of the tested cytokine. PBMCs were collected also 
from the healthy controls, in order to compare the Tregs and 
Tnull distributions with those of CRC patients.
Purification and Functional evaluation  
of blood Tregs
To assess the suppressive properties of Tregs isolated from the 
peripheral blood of CRC patients, we tested their ability to inhibit 
the proliferation of T effector cells (Teff), as previously described 
(36). Briefly, peripheral Tregs were magnetically separated 
from CRC patients’ PBMC, using the CD4+CD25+CD127dim/− 
Regulatory T Cell Isolation Kit (Miltenyi Biotec, Germany): cells 
eluted from the column constituted Tregs, whereas T  cells not 
retained by the magnetic field were accounted as Teff. Tregs and 
Teff were cultured alone or together at a 1:1 ratio in complete 
medium, with or without polyclonal stimulation [1 µg/ml, low-
endotoxin anti-CD3 and anti-CD28 monoclonal antibodies 
(BD Biosciences)]. The stimulation was carried out immediately 
after BD Horizon Violet Proliferation Dye 450 (VPD450, BD 
Biosciences) incorporation. The proliferation of Teff, alone or in 
the presence of Tregs, was assessed after 5-day incubation by flow 
cytometry.
statistical analysis
The analysis was performed using SPSS statistical software 
(version 24) and the data were expressed as the mean ± SD for 
continuous variables. Comparisons between the two groups 
were assessed using the Student’s t-test. Correlations between 
the parameters were assessed using Pearson correlation analysis. 
One-way ANOVA test was performed to compare three or more 
groups with Turkey’s multiple comparison test. SPSS was used 
for all the statistical analyses. A multiple regression analysis 
was performed to correlate Tregs percentage values and clinical 
parameters. p Values of less than 0.05 were considered significant.
resUlTs
characterization of crc Tumor-infiltrating 
lymphocytes (Tils)
To evaluate the intra-tumoral immune response in CRC patients, 
we expanded and cloned in  vivo-activated TILs, isolated from 
three different sites (CT, MT, and HM). We obtained Tcc from 
each patient (Table 1) for a total number of 781 Tcc: taking into 
account all patients, the number of Tcc obtained (529) from the 
tumor tissue (CT + MT) was higher than those obtained from 
HM (252). In detail, we have isolated 315 Tcc from the tissue 
of CT and 214 from the MT. Eighty-five percent (664/781) of 
isolated Tcc were positive for CD4 with a similar distribution on 
the evaluated cancer tissues: 264, 220, and 180 from CT, MT, and 
HM, respectively. Noteworthy, of the obtained 117 CD8+ Tcc, 
only seven (7/117, 6%) were isolated from the HM, the majority 
(94%) was isolated from the tumor tissue (54 from CT and 56 
from MT) (Figure 1).
Based on the cytokine profile and the CD4/CD8 expression, 
most of the CD4+Tcc (306/664, 46%) was Th1 with a similar per-
centage distribution into the different tissue sites: 96/180 (53%) 
in HM, 99/220 (45%) in the MT, and 111/264 (42%) in the CT 
(Figure 2A). A considerable fraction (219/664, 33%) of the CD4+ 
Tcc was able to produce IL-17, in detail, 57 out of 180 Tcc (32%) 
isolated from HM, 70 of 220 (32%) from MT, and 92 out of 264 
(35%) obtained from the CT (Figure 2A). It is remarkable that 
62% (136/219) of Th17 clones produced both IL-17 and IFN-γ 
FigUre 2 | The cytokine phenotype distribution of CD4+ T-cell clones (a) and CD8+ T-cell clones (b). The percentages of CD4+ [T helper1 cells (Th1), Th17, Th0, 
Treg, Tnull] and of CD8+ (Tc1, Tcreg, Tnull) T cell clones (Tcc) subpopulations were calculated comparing the number of Th/Tc types with the total number of CD4/
CD8 clones obtained from the same tumor tissue sites [healthy mucosa (HM), marginal tumor (MT), and central tumor (CT)]. (c) A representative flow cytometry 
analysis of a CD4+ Treg clone: anti-CD4, anti-CD25, anti-FoxP3, anti-TGFβ, anti-IL-10 mAb, and isotype controls.
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(data not shown). 13 of the remaining CD4+ Tcc produced IL-4 
alone: 6 from the MT (3%) and 7 from the CT (3%). Forty CD4+ 
Tcc showed a Th0 profile: 30 from the MT (14%) and 10 from the 
CT (4%) (Figure 2A). Of note, the Tcc with Th0 or Th2 profile 
have only been isolated from cancer tissue (marginal +  CT). 
Finally, 86 CD4+ Tcc (13%) was unable to produce any of the 
tested cytokines [not effector T cell clones (neT Tcc)].
Regarding the cytokine profile of the CD8+ population, we 
found that the majority of these Tcc have been isolated from the 
cancer tissue (110) and that 53 showed a Tc1 profile (producing 
IFN-γ), in detail 26/56 (46%) from MT and 27/54 (50%) from CT. 
Finally, all the seven CD8+ Tcc isolated from HM secreted only 
IFN-γ, showing a Tc1 profile (Figure 2B). The 49% of CD8+ Tcc 
did not produce the tested cytokines (neT Tcc).
In addition, we have evaluated the IFN-γ amount secreted by 
the Tcc with Th1 profile isolated from the three different tumor 
sites. We learnt that the Th1 isolated from HM significantly 
(p < 0.0001) produced higher IFN-γ amount compared to that 
produced by Th1 Tcc generated from both marginal and CT 
(Figure 3).
intra-Tumoral Tregs in crc Patients
Evaluating the T cell cytokine profile, we found that a high num-
ber (86/664) of CD4+ (13%) and 57 of 117 CD8+ (49%) T cells was 
unable to produce any of the tested cytokines, namely neT Tcc. 
To clarify the nature of these Tcc we subsequently analyzed FoxP3 
expression, along with TGF-β and IL-10 production.
Seventy of the 86 CD4+ (81%) neT Tcc isolated were FoxP3+ 
and produced IL-10 alone or in combination with TGF-β, show-
ing a definite Tregs profile (Figure  2C), while we defined the 
remaining 16 (19%) of them as Tnull, because were FoxP3− and 
unable to secrete both IL-10 or TGF-β. In detail, we have isolated 
20 Tregs from HM and 50 from the tumor site (40 CT and 10 
MT). About the Tnull population, we have obtained 7 Tcc from 
the HM and 5 and 4 Tcc from marginal and CT, respectively. 
Therefore, we have isolated Tnull and Tregs at both the sites. The 
Tregs’ percentage is higher in the CT (15%) than in HM (11%), 
and the percentage of Tnull is slightly higher in HM (4%) than in 
CT (2%), and MT (2%) (Figure 2A).
Regarding the 57 CD8+ neT Tcc, the majority (50, 88%) 
showed a Tcreg profile (FoxP3+ and IL-10+) and only 7 (12%) 
were FoxP3− and unable to secrete IL-10, namely Tcnull. In 
detail, of the 54 CD8+ Tcc isolated from the CT 24 (44%) showed 
a regulatory profile while three (6%) were Tcnull. Similarly, from 
the MT, we have obtained 26 Tcreg (46%) and four Tcnull (7%) 
(Figure 2B).
To rule out the possibility that Tnull/Tcnull clones were naive 
T  cells, we have analyzed the expression of CCR7, CD45RA, 
FigUre 3 | The different interferon (IFN)-γ amount (pg/ml) secreted by the 
T cell clones with T helper1 cells (Th1) profile, isolated from the tumor tissue. 
We measured the interferon (IFN)-γ production in culture supernatants by 
specific test ELISA. Th1 cell clones isolated from healthy mucosa significantly 
produced higher IFN-γ amount compared to that produced by Th1 cell 
clones generated from both marginal and central tumor. The error bars 
represent the SD. Statistical analyses were calculated using one-way ANOVA 
and Turkey’s post hoc. The asterisks (*) represent p-values, *p < 0.05, 
**p < 0.01, ***p < 0.001.
FigUre 4 | A representative cytofluorimetric analysis (CCR7, CCD28, 
CD45RO, CD45RA, and isotype controls) of a CD4+ Tnull clone obtained 
from the central tumor of a colorectal cancer patients.
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CD45 RO, and CD28 confirming their memory phenotype 
(Figure 4).
Functional Profile of intra-crc Tcc
Using the P815 cells as targets, we have assessed the cytolytic 
potential of Tcc (CD4+ and CD8+) with Th1 profile or Tnull; we 
have observed that all the Th1/Tc1Tcc showed an expression of 
granzyme A around 40% or slightly more, especially the CD8+ 
Tcc (Figures 5A,B). While, as expected, the Tcc with Tnull profile, 
as CD4+ (Figure 5A) as CD8+ (Figure 5B), are unable to kill the 
target cells.
Of note, the cytotoxic activity was different in the various Th1/
Tc1 clones, isolated from the different tumor sites. As expected, 
the expression of granzyme A was significantly higher in Th1/
Tc1Tcc isolated from HM compared to that released from the 
tumor tissue counterparts (Figures 5A,B,D).
In addition, we have observed that the intra-tumoral Tcc 
with Th17 profile were able to kill the target cells, only if they 
co-produced IFN-γ (data not shown).
Finally, we have assessed the ability of Tcc to induce apoptosis. 
All the Tnull Tcc displayed a very low percentage of AnnexinV-
binding cells (<1%). Only the Tcc (as CD4+ as CD8+) with Th1 
profile displayed a higher percentage. In addition, similar to what 
observed for the cytotoxicity, the Th1/Tc1 Tcc isolated from HM 
showed a major aptitude to kill the target inducing apoptosis 
(Figure 5C).
FigUre 5 | Cytotoxicity profile of T cell clones (Tcc) isolated from the different tumor sites. The granzyme A expression of CD4+ (a) and CD8+ (b) Tcc, and the 
percentage of annexin V-binding cells (c) were assessed according to the manufacturer’s instructions and analyzed on a FACSCanto cytofluorimeter (BD 
Biosciences) using FACSDiva software. The error bars represent the SD. Statistical analyses were calculated using one way ANOVA and Turkey’s post hoc. The 
asterisks (*) represent p-values, *p < 0.05, **p < 0.01, ***p < 0.001. (D) A representative dot plots indicating the granzyme A expression (percentage) of CD4 + Th1 
and Tnull Tcc isolated from healthy mucosa (HM), marginal tumor (MT), and central tumor (CT).
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cytofluorimetric assessment of  
intra-Tumoral T cells’ Distribution  
in crc Patients
From the dissociated HM of all CRC patients and the CT tis-
sue of 20 (out of 30), we performed a cytofluorimetric analysis 
of “fresh” infiltrating T  cells (Figures  6A,C). As shown in 
Figure 6A, the CD4+ TILs isolated from CT contained a smaller 
percentage of Th1 (45.61 ± 3.11 vs 53.54 ± 3.53; p < 0.0001) 
and higher percentages of Th17 (14.30 ± 1.12 vs 6.21 ± 2.18; 
p <  0.0001), Treg (6.25 ±  0.81 vs 3.56 ±  1.12; p <  0.0001), 
Th2 (4.26 ± 1.12 vs 2.21 ± 0.90; p < 0.0001), and Tnull cells 
(2.31 ±  0.66 vs 1.12 ±  0.32; p <  0.0001) than TILs isolated 
from HM. In a similar way, CT contained a smaller percentage 
of Tc1 and a higher percentage of Tc17, Tcreg, and Tcnull than 
HM. Moreover, both CD4+ and CD8+ (Figure 6B) subsets of 
the TILs’ population mirror the distribution of Tcc obtained 
from the HM and CT.
evaluation of circulating T cell subsets  
in crc Patients
By flow cytometry, we analyzed the distribution of T cell subsets in 
the peripheral blood of CRC patients. 61 ± 4.3% of peripheral T cells 
was positive for CD4+, while 15 ± 2.2% was CD8+. The mean per-
centages of CD4+ and CD8+ circulating T cell subsets obtained from 
the 30 CRC patients’ blood samples (collected at T = 0) are reported 
in Figure 7. The percentage of circulating Tregs registered in the 
CRC patients (3.58 ± 0.88) was significantly (p < 0.0001) higher 
compared to that of healthy controls (2.59 ± 0.62, Figure 8); anyway, 
multiple regression analysis did not show any correlation between 
preoperative circulating Tregs’ percentage values and age, sex, serum 
CEA level, and degree of histologic differentiation. The percentage 
of circulating CD4+ Tnull in CRC patients (1.17 ± 0.41) was signifi-
cantly (p < 0.0001) higher than healthy controls (0.45 ± 0.23).
In addition, the percentage of circulating Tregs dropped sig-
nificantly at T = 14 (2.72 ± 0.79) (p < 0.0001) and overlapped the 
FigUre 6 | Cytofluorimetric analysis of fresh TILs isolated from tissue specimens. (a) Different distribution of fresh CD4+ and CD8+ TILs subsets, isolated from the 
healthy mucosa (HM) of 30 colorectal cancer (CRC) patients and the central tumor (CT) of 20 (out of 30). Results are reported as percentages (mean ± SD) and 
statistical analysis was performed using the Student’s t-test. The asterisks (***) represent a p < 0.001. (b) Comparison of CD4+ and CD8+ T cell subsets’ 
distribution, obtained by analysis of fresh TILs and Tcc obtained by cloning, in HM and CT of CRC patients. (c) A representative cytofluorimetric analysis of fresh  
T helper subsets (Th1, Th17, Th2, Treg) observed in HM and CT of the same CRC patients.
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values recorded in healthy controls (Figure 8A); conversely, the 
percentage of Tnull diminish, but not significantly, in the postop-
erative (0.99 ± 0.37) (Figure 8B). Of note, we have observed that 
the CRC patients with the highest percentage of circulating Tregs 
were those who exhibited a greater number of intra-tumoral 
Tregs, in particular patients 2, 4, 13, and 25.
assessment of Tregs Function
Finally, in a reduced number (n = 22) of patients, we obtained a 
suitable number of Tregs for the functional assays. First, by flow 
cytometry, we assessed the purity of the CD4+CD25high T  cell 
population, which was, in all cases, >90% (mean ± SD 93.6 ± 1.5; 
median 93.3; range 91.6–95.7). In a 1:1 ratio with Teff, Tregs were 
shown to inhibit growth of polyclonally stimulated Teff as dem-
onstrated by tracking of VPD450 incorporation in lymphocytes 
by means of flow cytometry (data not shown). Therefore, the 
CD4+CD25+CD127dim/− T phenotype was confirmed to belong to 
a T cell subset with immunosuppressive features.
DiscUssiOn
In this study, we analyzed the peripheral and intra-tumoral 
T  cell response in patients with CRC. To evaluate the intra-
tumoral immune response, we isolated and characterized TILs 
from three different sites: the CT, the MT, and surrounding HM. 
In all three sites, the analysis of TIL clonal progeny has shown 
a large predominance of CD4+ T  cells compared to the CD8+ 
T cell population. While the CD4+Tcc had a similar distribution 
in the three different sites, CD8+ Tcc were notably numerous on 
cancer tissue than HM. The TIL cytokine profile demonstrated 
that most CD4+ and CD8+ Tcc predominantly produced IFN-γ 
and a considerable fraction of CD4+ Tcc, but none of the CD8+ 
Tcc, also secreted IL-17 alone or in combination with IFN-γ. For 
their cytotoxic activity, Th1/Tc1 cells are critical in the antitumor 
response (11), while the role of IL-17 in tumorigenesis has not 
been clarified (37). Various studies reported the ability of Th17 
to promote cancer growth; in particular, in CRC, Galon and 
collaborators found that a high infiltration of IL-17+ T cells was 
negatively correlated with patient’s prognosis (20), and Sharp 
et al. demonstrated that advanced stage colon cancer was asso-
ciated with elevated Th17-associated cytokines (14). Anyway, 
endogenous IL-17 or/and Th17 cells may play a protective role 
in tumor immunity (13, 38, 39); for example, levels of tumor-
infiltrating Th17 cells were reduced in advanced ovarian cancer 
patients, which appeared to correlate with a positive outcome 
(39). In pancreatic cancer, we have demonstrated the effectors 
functions of antigen specific Th1/Th17 Tcc (40) supporting 
the theory that, when Th17 turn into IFN-γ-expressing Th17 
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(Th17/Th1  cells), they can contribute to protective antitumor 
immunity, eradicating tumor cells through production of IFN-
γ, or inducing Th1-type chemokines and stimulating CXCL9 
and CXCL10 production to recruit effector cells to the tumor 
microenvironment (39, 41, 42). Regarding CRC, Amicarella and 
collaborators revealed a positive contribution of Th17  cells to 
beneficial antitumor immune responses in CRC and underline 
their pleiotropic function resulting from the production of a 
broad spectrum of cytokines and chemokines beyond IL-17 
(13). Therefore, to confirm their effector functions, we tested the 
cytotoxic properties of the IFN-γ producing Tcc, both Th1/Tc1 
and Th1/Th17, isolated from CRC patients. We found that they 
were all able to kill cancer cells, but the percentage of effectors 
T cells decreased in cancer tissue than in HM and, interestingly, 
the amount of IFN-γ produced by CD4+ Tcc isolated from HM 
was significantly higher compared to that produced by Th1 
Tcc generated from both MT and CT. These data highlight an 
impairment of the antitumor immune response in the tumor 
sites. Moreover, the cytotoxic activity was different in the vari-
ous Th1/Tc1 clones, isolated from the different tumor sites: in 
fact, the expression of granzyme A was significantly higher 
in Th1/Tc1 Tcc isolated from HM compared to that released 
from the tumor tissue counterparts, suggesting that the tumor 
microenvironment negatively influences the cytolytic activity of 
T lymphocytes reactive to tumor cells.
Another interesting data are the presence in the cancer tis-
sues, but not in HM, of CD4+ Tcc able to secrete IL-4 alone or in 
combination with IFN-γ, showing a Th2/Th0 profile; notoriously, 
these cells can favor cancer progression and particularly in CRC, 
it is reported that Th1 cell predominance is correlated with a good 
prognosis, whereas a high proportion of Th2 cells is correlated 
with a worse prognosis (43, 44). Anyway, the most striking data 
shown by our analysis are that the tumor is infiltrated by a large 
amount of Tcc with regulatory or “non-functional” profile. In fact, 
the 13% of CD4+ Tcc and the 49% of CD8+ Tcc did not display 
effector properties.
We have isolated CD4+ neT Tcc from all the three sites, and 
the 11% of them have proved to be Tregs, while the 2% were 
Tnull. The Tregs’ percentage was higher in the CT than in the 
surrounding HM, and the percentage of Tnull was slightly 
higher in HM than in CT and MT. About the CD8+ neT Tcc, 
the majority showed a Tcreg profile (43%) while the 6% were 
Tcnull, with a similar distribution in MT and CT; none CD8+ 
neT Tcc was isolated from the HM. So, the CRC tissue is mas-
sively infiltrated by CD8+ T cells, but many of them (about half 
of the isolated Tcc) have a regulatory profile or are anergic, i.e., 
FigUre 7 | Percentages of CD4+ and CD8+ circulating T cells’ subsets present in colorectal cancer patients’ blood on the day of the surgery (T = 0). Evaluation of 
the T cell subsets was performed by flow cytometry basing on specific markers’ expression. T helper and T cytotoxic subsets are reported as percentages 
(mean ± SD) of total CD4+ or CD8+ T cells, respectively.
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not able to produce cytokines with anticancer role [primarily, 
IFN-γ (45)].
We demonstrated the functional anergy of CD4+ and CD8+ 
Tnull clones by their inability to lyse target cells. Dysfunctional 
CD4+ and CD8+ T cells have been defined in both cancer patients 
and experimental models (16, 17, 46). These cells include 
exhausted, anergic, and regulatory/senescent T cells. Exhausted 
T cells are a persistent T cell population characterized by the low 
cytokine production, reduced cytotoxic activity, and reduced 
proliferative potential (47, 48). Anergy refers to a hyporespon-
sive state of impaired IL-2 production and proliferation, result-
ing from inefficient costimulation and/or high co-inhibitory 
signaling or from partial or chronic TCR stimulation (17). 
T cell exhaustion represents a distinct but reversible T cell fate 
in the context of antitumor immune responses and moreover, 
many studies suggest that immunosuppressive mechanisms in 
the tumor microenvironment are capable to promote an anergic 
phenotype (49). In CRC patients, a recent study demonstrated 
the functional impairments in the cytokine production and 
proliferation of T  cells infiltrating tumor, probably related to 
T cell exhaustion (15). Similarly, populations of Tregs have been 
largely identified in cancer, and are usually considered able to 
protect cancer cells from antitumor immunity. In fact, they are 
capable to block the T-cell-mediated immune response against 
human tumors (50), including CRC (51), and the presence of 
Tregs is correlated with a poor prognosis in various cancers 
(27, 52, 53). However, recent conflicting reports show that 
high expression of Tregs is correlated with a good prognosis, 
especially in CRC (10).
The Tregs’ protective role may depend on their control of 
inflammation associated with neoplastic transformation and 
cancer progression (54–57). We, in agreement and supported 
by other study, believe that Tregs can play protective roles prior 
to cancer initiation in “inflammation-prone” cancers but, after 
the tumor establishment, the Tregs can be co-opted by tumors 
assuming a pro-tumorigenic role (58). In fact, an accumulation 
of highly suppressive and activated FoxP3+ Tregs in the tumor 
tissue of CRC patients has also been reported to correlate with 
tumor progression (59–61). Moreover, today, it is well known 
that various Tregs subsets exist, which differ in their suppressive 
ability, i.e., “effectors Tregs” or “non-Tregs” (33). About them, 
a recent study showed that CRC patients can be separated 
into two groups: (i) with tumors infiltrated predominantly by 
suppression-competent effectors Tregs and (ii) with tumors 
infiltrated with a sizable fraction of Foxp3+ non-Tregs in addi-
tion to effectors Tregs (62). In the latter group, Foxp3+ non-Tregs 
secrete inflammatory cytokines and the cytokine production 
is correlated with expression of TGF-β and IL-12 genes in the 
cancer cells. In this group, high Foxp3 gene expression shows 
significantly better prognosis than low Foxp3 gene expression. 
By contrast, in the group with tumors infiltrated predominantly 
by effectors Tregs, high Foxp3 gene transcription indicates poor 
prognosis compared with low Foxp3 transcription. Hence, the 
Tregs’ subsets can play a contrasting role in tumor immunity and 
to identify suppressive Tregs it is critical to test their immuno-
suppressive properties through functional assays. As reported 
above, in our study, we have observed a considerable number 
of intra-tumoral Tregs in CRC patients, and interestingly their 
FigUre 8 | Evaluation of circulating CD4+ Treg (a) and Tnull (b) cells in blood samples of 30 colorectal cancer (CRC) patients and 30 healthy subjects. The 
evaluation of the T cells’ subsets was performed by flow cytometry (basing on the expression of specific markers) and at different time points: the day of the surgery 
(T = 0) and 2 weeks after (T = 14). The error bars represent the SD. Statistical analyses were calculated using one-way ANOVA and Turkey’s post hoc. The asterisks 
(*) represent p-values, *p < 0.05, **p < 0.01, ***p < 0.001.
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prevalence was higher in cancer tissue than in surrounding HM, 
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